Media coverage about NanoViricides (NASDAQ:NNVC) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. NanoViricides earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.5048214520696 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
NanoViricides (NASDAQ NNVC) opened at $1.02 on Friday.
NanoViricides Company Profile
NanoViricides, Inc is a nano-biopharmaceutical company. The Company is a development-stage company with several drugs in various stages of development. The Company focuses on its research and clinical programs on specific anti-viral therapeutics. The Company is engaged in the application of nanomedicine technologies to the issues of viral diseases.
What are top analysts saying about NanoViricides Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NanoViricides Inc and related companies.